Conference Track

Colorectal Cancer

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Clinical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

High-Dose Bevacizumab Plus FOLFOX4 Improves Response Rate and Survival in Previously Treated Advanced Colorectal Cancer
Addition of PTK/ZK to FOLFOX4 Improves PFS in Patients With Metastatic Colorectal Cancer
Adjuvant Therapy With Irinotecan Plus Infusional 5-Fluorouracil/Folinic Acid Delays Recurrence in Patients With Stage 3 Colon Cancer
Oxaliplatin Added to Weekly 5-FU/LV Bolus Significantly Improves Disease-Free Survival in Colon Cancer Patients
MOSAIC Trial Update: Continued Improved Disease-Free Survival at 4 Years for Patients With Stage 2 and 3 Colon Cancer Treated With FOLFOX4 vs LV5FU2
Adding Irinotecan to LV5FU2 Does Not Improve Disease-Free Survival in Patients With High-Risk Colon Cancer
CAPOX and FUFOX Efficacy and Toxicity Comparable in Patients With Metastatic Colorectal Cancer
Concurrent Cetuximab/Bevacizumab Feasible and Promising in Irinotecan-Refractory CRC Patients
Bevacizumab Improves Response to Oxaliplatin Plus 5-FU/Leucovorin in Patients with Previously Untreated Metastatic Colorectal Cancer
Capecitabine Improves Disease-Free and Relapse-Free Survival in Colorectal Carcinoma
Capecitabine Plus Oxaliplatin (XELOX): Safety Assessment in Phase 3 Study of Patients with Stage III Colorectal Cancer
Capecitabine With Oxaliplatin (XELOX): Efficacy and Safety in Phase 2 Study of Elderly Patients With Metastatic Colorectal Cancer

Expert Analysis

Colorectal Cancer

Program Director:
Roy A. Beveridge, MD

Faculty:
Syma Iqbal, MD John L. Marshall, MD Lee S. Rosen, MD
Alan P. Venook, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data on the use of fluoropyrimidines for treatment of colorectal cancer
Describe investigations of targeted therapeutic approaches to treating colorectal cancer
List current therapies under investigation for treatment of stage II and III colon cancer

Earn CME credit by reading the expert analysis and commentary on colorectal cancer. Topics covered include:

PETACC-3: Irinotecan Plus 5-FU/FA in Stage 3 Colon Cancer
ACCORD: Irinotecan + LV5FU2 in High-Risk Colon Cancer
NSABP Protocol C0-7
MOSAIC 4-year Update
Updated Efficacy and Safety From X-ACT
Bevacizumab Plus FOLFOX4 in Advanced Colorectal Cancer
CONFIRM-1 Trial: PTK/ZK in Metastatic CRC
CapOx ± Bevacizumab in Metastatic Colorectal Cancer
CapOx in Elderly Patients with Colorectal Cancer
Treatment of Refractory Colorectal Cancer

CME CREDIT INFORMATION

Release Date: 07/20/05

Expiration Date: 07/19/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.8 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.